What’s the current market cap for H. Lundbeck A/S stock?

H. Lundbeck A/S (HLUNB) has a market cap of €5.6bn as of June 16, 2026.

What is the P/E ratio for H. Lundbeck A/S stock?

The price to earnings (P/E) ratio for H. Lundbeck A/S (HLUNB) stock is 11.5 as of June 16, 2026.

Does H. Lundbeck A/S stock pay dividends?

Yes, the H. Lundbeck A/S (HLUNB) stock pays dividends to shareholders. As of June 16, 2026, the dividend rate is €0.15391 and the yield is 2.66%. H. Lundbeck A/S has a payout ratio of 30.59% on a trailing twelve-month basis.

When is the next H. Lundbeck A/S dividend payment date?

The next H. Lundbeck A/S (HLUNB) dividend payment date is unconfirmed.

What is the beta indicator for H. Lundbeck A/S?

H. Lundbeck A/S (HLUNB) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy H. Lundbeck A/S stock | €HLUNB Share Price

05:30

09:10

12:45

16:25

20:00

About H. Lundbeck A/S

H. Lundbeck A/S is a Danish pharmaceutical company focused on the research, development, production, and marketing of pharmaceuticals for the treatment of brain disorders. Headquartered in Copenhagen, Denmark, Lundbeck's core business includes a portfolio of products addressing conditions such as depression, anxiety, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company has a significant presence in the neuropharmaceuticals industry, striving to deliver innovative solutions to patients with unmet medical needs. Lundbeck operates internationally, distributing its products across multiple markets, supported by its strategic positioning in research and development. Unique competitive strengths include its dedicated focus on central nervous system disorders and ongoing investments in innovative therapies.

Ticker

€HLUNB

Sector

Health

Primary listing

XGAT

Employees

5,000

Headquarters

Valby, Denmark

Website

www.lundbeck.com

H. Lundbeck A/S Metrics

BasicAdvanced

€5.6bn

11.50

€0.50

0.26

€0.15

2.66%

Bulls say / Bears say

In May 2026, Lundbeck raised its 2026 revenue growth guidance to 7–9% at constant exchange rates and adjusted EBITDA growth to 8–14%, driven by stronger U.S. demand for Vyepti and a delayed generic launch of Abilify Maintena, underscoring confidence in its core CNS portfolio (Reuters)

Lundbeck’s Q1 2026 revenue rose 21% at constant exchange rates to DKK 7.13 billion, with underlying growth of 13% after adjusting for a one-off DKK 470 million inventory build, reflecting robust demand across its strategic CNS brands (Reuters)

CEO Charl van Zyl stated that Lundbeck’s pipeline assets are advancing well, strengthening the company’s long-term growth potential and highlighting progress on novel CNS therapies (Reuters)

Jefferies warns that approximately 60% of Lundbeck’s sales are at risk due to looming patent expiries on key franchises such as Rexulti and Abilify Maintena, exposing the company to significant revenue erosion beginning in 2026 (Reuters)

Most new drugs in Lundbeck’s pipeline are unlikely to reach the market before 2028, leaving a growth gap that may not offset the impact of patent cliffs on existing products (Reuters)

Jefferies cautions that demand for Vyepti is constrained to later-stage and severe migraine cases, limiting the therapy’s near-term revenue expansion despite broader market potential (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy €HLUNB

€

Capital at risk

Extended hours trading

Upcoming events

No upcoming events

Bulls say / Bears say

CEO Charl van Zyl stated that Lundbeck’s pipeline assets are advancing well, strengthening the company’s long-term growth potential and highlighting progress on novel CNS therapies (Reuters)

Most new drugs in Lundbeck’s pipeline are unlikely to reach the market before 2028, leaving a growth gap that may not offset the impact of patent cliffs on existing products (Reuters)

Jefferies cautions that demand for Vyepti is constrained to later-stage and severe migraine cases, limiting the therapy’s near-term revenue expansion despite broader market potential (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2026.

About H. Lundbeck A/S

Ticker

Primary listing

Employees

Headquarters

H. Lundbeck A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €HLUNB

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

H. Lundbeck A/S/€HLUNB

About H. Lundbeck A/S

Ticker

Primary listing

Employees

Headquarters

H. Lundbeck A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €HLUNB

Upcoming events

No upcoming events

What’s the current market cap for H. Lundbeck A/S stock?

What is the P/E ratio for H. Lundbeck A/S stock?

Does H. Lundbeck A/S stock pay dividends?

When is the next H. Lundbeck A/S dividend payment date?

What is the beta indicator for H. Lundbeck A/S?

Bulls say / Bears say